clinic
applic
human
multipot
mesenchym
stromal
cell
msc
cell
therapi
tissu
engin
regen
medicin
treatment
immun
inflammatori
diseas
requir
phase
isol
ex
vivo
expans
allow
clinic
meaning
cell
number
reach
condit
use
cell
isol
expans
meet
strict
qualiti
safeti
requir
particularli
true
growth
medium
use
msc
isol
expans
basal
growth
media
use
msc
expans
supplement
multipl
nutrient
growth
factor
fetal
bovin
serum
fb
long
gold
standard
medium
supplement
laboratoryscal
msc
cultur
howev
fb
poorli
character
composit
pose
risk
factor
may
sourc
xenogen
antigen
zoonot
infect
fb
therefor
becom
undesir
growth
medium
supplement
isol
expand
msc
human
therapi
protocol
recent
year
human
blood
materi
particularli
lysat
releas
platelet
concentr
emerg
effici
medium
supplement
isol
expand
msc
variou
origin
review
analyz
advantag
limit
use
human
platelet
materi
medium
supplement
msc
isol
expans
present
mode
product
allogen
autolog
platelet
concentr
measur
taken
ensur
optim
pathogen
safeti
profil
method
prepar
pl
msc
expans
also
discuss
suppli
blood
prepar
produc
optim
condit
standard
safeti
human
platelet
materi
becom
futur
gold
standard
supplement
ex
vivo
product
msc
translat
medicin
cell
therapi
applic
stem
cell
sc
base
therapi
use
multipot
mesenchym
stromal
cell
msc
deriv
adult
tissu
mesoderm
origin
great
potenti
variou
clinic
applic
cell
therapi
tissu
engin
regen
medicin
treat
immun
inflammatori
diseas
current
clinic
applic
use
msc
includ
treatment
bone
diseas
repair
cartilag
control
graft
versu
host
diseas
facilit
engraft
bone
marrow
transplant
treatment
myocardi
infarct
research
clinician
alik
hope
sc
therapi
prove
benefici
therapeut
field
treat
musculoskelet
damag
cancer
neurolog
disord
one
technic
impair
practic
use
mscbase
cell
therapi
regen
medicin
immunosuppress
low
level
cell
present
tissu
bone
marrow
umbil
cord
blood
adipos
tissu
dental
pulp
etc
thu
mani
clinic
indic
msc
isol
expand
ex
vivo
reach
clinic
meaning
cell
count
need
therapeut
use
differenti
select
environ
variou
cell
lineag
like
osteoblast
chondrocyt
myoblast
hepatocyt
neuron
cell
vascular
smooth
muscl
cell
accept
clinic
applic
phase
ex
vivo
expans
achiev
safe
cultur
condit
meet
requir
good
manufactur
practic
gmp
good
tissu
cultur
practic
key
complianc
factor
growth
medium
use
cultur
success
msc
isol
cultur
protocol
requir
special
media
contain
enrich
substrat
protein
bioactiv
molecul
growth
factor
variou
nutrient
fetal
bovin
serum
fb
also
often
refer
fetal
calf
serum
use
supplement
basal
cultur
medium
need
success
ex
vivo
expans
msc
still
repres
gold
standard
medium
supplement
cell
cultur
set
regulatori
approv
cell
therapi
clinic
trial
base
msc
grown
fbssupplement
media
imped
due
two
wellidentifi
drawback
fb
first
despit
attempt
clear
bovin
protein
msc
expans
residu
bovin
compon
may
induc
immun
reaction
msc
recipi
particular
immunogen
xenocarbohydr
structur
may
intern
cell
cultur
possibl
explain
msc
transplant
failur
indirect
evid
sideeffect
come
rodent
experiment
studi
strong
immunogen
reaction
origin
fbsbase
cultur
medium
observ
similarli
inocul
human
peptidepuls
dendrit
cell
grown
fbssupplement
medium
patient
malign
melanoma
result
gener
immunoglobulin
g
igg
igm
antibodi
bovin
protein
occurr
anaphylact
reaction
likewis
gener
antibodi
fb
compon
develop
arthuslik
reaction
observ
human
immunodefici
viru
hiv
infect
patient
receiv
multipl
infus
lymphocyt
ident
twin
sibl
cultur
medium
supplement
fb
took
place
despit
thorough
wash
cell
infus
second
regulatori
safeti
concern
risk
zoonot
infect
associ
use
fb
recent
occurr
natur
transmiss
zoonot
diseas
illustr
possibl
exchang
human
natur
reservoir
biolog
agent
found
anim
inher
risk
emerg
diseas
exampl
infect
origin
anim
pathogen
includ
hiv
ebola
hanta
lassa
nipah
virus
paramyxovirus
equin
morbilli
viru
west
nile
viru
wnv
sever
acut
respiratori
syndrom
sar
coronaviru
recent
flu
viru
new
middl
east
respiratori
syndrom
coronaviru
merscov
infecti
risk
bovin
sourc
includ
transmiss
virus
bovin
viral
diarrhea
viru
bovin
parvoviru
prion
respons
bovin
spongiform
encephalopathi
bse
mad
cow
diseas
cow
human
equival
variant
creutzfeldtjakob
diseas
vcjd
world
health
organ
sever
regulatori
author
recommend
restrict
even
ban
use
materi
bovin
origin
particularli
therapeut
applic
includ
cell
therapi
protocol
addit
drawback
fb
includ
wellrecogn
inconsist
qualiti
requir
test
sampl
sever
lot
identifi
suitabl
batch
given
msc
sourc
b
grow
ethic
concern
suffer
impos
anim
product
method
serum
calv
anim
serumfre
media
search
fb
substitut
chemicallydefin
media
attempt
develop
chemic
defin
medium
supplement
use
nutrit
sourc
exclus
nonanim
origin
recombin
growth
factor
combin
plateletderiv
growth
factor
pdgf
fibroblast
growth
factor
fgf
transform
growth
factor
tgf
b
epithelium
growth
factor
egf
far
turn
practic
feasibl
expand
msc
contrast
achiev
wellestablish
stabl
cell
line
produc
recombin
therapeut
protein
difficulti
use
chemicallydefin
media
primari
cell
cultur
may
associ
inher
variabl
specif
addit
anticip
chemic
defin
media
specif
mix
growth
factor
develop
adjust
sourc
sc
eg
bone
marrow
adipos
tissu
cord
blood
dental
pulp
etc
even
possibl
donor
singl
growth
factor
expect
readili
provid
divers
physiolog
function
exhibit
complex
protein
nutrient
supplement
fb
limit
number
licens
growth
factor
compli
therapeut
applic
complic
develop
chemicallydefin
media
use
human
blood
materi
possibl
complement
mix
recombin
growth
factor
appear
pragmat
safest
approach
avail
far
substitut
fb
expand
clinicalgrad
sc
initi
use
human
blood
plateletderiv
materi
human
serum
sourc
essenti
nutrient
attach
factor
growth
factor
cell
growth
report
somewhat
controversi
scientif
rational
behind
use
presenc
wide
rang
growth
factor
entrap
platelet
platelet
thrombocyt
concentr
rang
irregularli
shape
nonnucl
bodi
releas
blood
fragment
megakaryocyt
vivo
platelet
play
major
role
hemostasi
assist
format
blood
clot
blood
vessel
wound
heal
injuri
physiolog
condit
growth
factor
releas
platelet
activ
releas
reproduc
vitro
prepar
growth
factorrich
fluid
one
first
clear
demonstr
posit
effect
growth
factorrich
human
blood
materi
ex
vivo
expans
bone
marrowderiv
bm
msc
best
knowledg
publish
author
use
platelet
gel
releas
obtain
vitro
thrombin
activ
plateletrich
plasma
prp
show
bmmsc
expand
medium
contain
human
platelet
releas
retain
abil
express
marker
chondrogen
osteogen
differenti
sever
passag
two
year
later
clearli
demonstr
growth
medium
supplement
platelet
concentr
lysat
sole
sourc
nutrient
could
use
expand
human
bmmsc
lysat
made
apheresi
platelet
concentr
frozen
subsequ
thaw
induc
platelet
lysi
releas
growth
factor
plasma
compart
platelet
concentr
lysat
centrifug
g
elimin
cell
debri
mean
respect
content
pdgfab
basic
b
fgf
insulinlik
growth
factor
approxim
ngml
significantli
fb
medium
supplement
platelet
lysat
pl
promot
bmmsc
expans
decreas
time
requir
reach
confluenc
increas
coloni
form
unitfibroblast
cfuf
size
compar
medium
contain
fb
immunophenotyp
expand
msc
modifi
least
four
passag
msc
maintain
abil
differenti
osteogen
chondrogen
adipogen
lineag
exert
immunosuppress
activ
sinc
pioneer
work
mani
addit
studi
conduct
gener
confirm
observ
group
compar
sever
type
blood
materi
includ
plasma
serum
pl
attempt
identifi
suitabl
given
type
msc
recent
review
indic
pl
activ
platelet
releas
superior
least
similar
fb
expand
bmmsc
adipos
tissuederiv
sc
content
platelet
materi
often
suffici
replac
fb
although
may
provid
optim
result
msc
human
blood
fraction
prepar
pl
describ
sever
mode
prepar
human
blood
materi
applic
ex
vivo
sc
expans
prepar
method
exert
signific
impact
platelet
leucocyt
plasma
protein
content
platelet
concentr
ultim
concentr
type
growth
factor
releas
therefor
import
document
way
platelet
concentr
blood
fraction
prepar
product
variabl
may
influenc
sc
expans
regen
capac
even
though
still
need
fulli
explor
examin
differ
mode
prepar
blood
compon
platelet
growth
factorrich
fraction
human
serum
prepar
use
growth
medium
supplement
let
whole
blood
collect
without
anticoagul
clot
overnight
serum
recov
centrifug
approxim
g
min
aliquot
kept
frozen
use
howev
human
serum
usual
avail
blood
establish
drawback
routin
applic
platelet
concentr
often
use
prepar
pl
sc
expans
fig
summar
main
product
mode
pl
materi
sc
expans
regen
medicin
recent
review
autolog
platelet
concentr
obtain
use
variou
type
medic
devic
differ
methodolog
platelet
separ
result
product
variabl
platelet
leucocyt
content
produc
variabl
rang
content
growth
factor
allogen
platelet
concentr
prepar
blood
establish
like
major
sourc
platelet
concentr
sc
expans
futur
three
basic
type
allogen
platelet
concentr
prepar
blood
establish
use
usual
day
storag
ae
longer
suitabl
transfus
start
materi
prepar
medium
supplement
msc
expans
process
may
may
subject
leucoreduct
step
usual
dedic
filtrat
reduc
content
white
blood
cell
wbc
may
exclus
formul
plasma
combin
plasma
addit
solut
product
compli
principl
gmp
ensur
meet
establish
characterist
transfus
use
whole
bloodderiv
platelet
concentr
obtain
byproduct
red
blood
cell
rbc
prepar
known
randomdonor
platelet
process
prp
buffi
coat
bc
typic
ml
whole
blood
collect
ml
anticoagul
solut
made
citrat
cell
nutrient
glucos
adenin
polyvinyl
chlorid
bag
donat
procedur
take
less
min
limit
risk
activ
blood
coagul
platelet
respect
donat
kept
h
ae
blood
cool
platelet
concentr
prepar
cool
temperatur
lead
loss
platelet
viabil
gener
platelet
leucocyt
microaggreg
first
centrifug
step
whole
blood
influenc
characterist
platelet
concentr
precis
condit
gforc
acceler
time
deceler
therefor
appli
impact
separ
variou
blood
compon
determin
addit
process
condit
need
obtain
platelet
concentr
defin
composit
prp
method
wholeblood
donat
subject
light
spin
centrifug
typic
g
min
condit
valid
segreg
rbc
upper
half
contain
platelet
plasma
mixtur
call
prp
platelet
concentr
heavi
spin
centrifug
g
min
valid
acceler
deceler
curv
platelet
concentr
bag
left
stationari
room
temperatur
approxim
h
concentr
resuspend
ml
plasma
platelet
deriv
whole
blood
mostli
produc
prp
method
us
bc
procedur
anticoagul
whole
blood
subject
hard
spin
centrifug
approxim
g
min
valid
acceler
deceler
curv
separ
cellfre
plasma
top
layer
middl
layer
call
bc
contain
roughli
platelet
wbc
rbc
rbc
bottom
layer
bc
layer
transfer
satellit
bag
ml
plasma
return
bc
layer
gentli
mix
subject
light
spin
centrifug
approxim
g
min
valid
acceler
deceler
curv
prp
supernat
place
platelet
storag
bag
store
ae
newer
procedur
part
plasma
replac
platelet
addit
solut
bc
method
favor
europ
leucocyt
deplet
bc
remov
reduc
frequenc
febril
transfus
reaction
facilit
high
level
leucodeplet
combin
leucocyt
filtrat
therefor
whole
bloodderiv
allogen
platelet
use
msc
expans
europ
like
deriv
bc
platelet
concentr
whole
blood
requir
pool
platelet
four
six
donat
obtain
adult
therapeut
dose
equival
singl
apheresi
platelet
procedur
autom
cell
separ
use
prepar
apheresi
platelet
concentr
close
system
dedic
extracorpor
procedur
collect
machin
use
intermitt
continu
centrifug
use
separ
collect
platelet
variou
cell
separ
avail
platelet
collect
differ
collect
principl
whole
blood
anticoagul
point
withdraw
control
manner
bloodanticoagul
ratio
compon
usual
return
donor
unless
also
collect
entir
procedur
take
least
h
platelet
concentr
larger
volum
typic
ml
total
platelet
content
fold
platelet
concentr
singl
wholeblood
donor
sever
variabl
platelet
concentr
product
method
influenc
platelet
leucocyt
protein
content
therefor
potenti
impact
msc
expans
instanc
apheresi
platelet
concentr
usual
significantli
lower
wbc
contamin
standard
bcderiv
prpderiv
platelet
concentr
addit
platelet
undergo
physiolog
function
chang
upon
storag
may
affect
therapeut
benefit
recipi
whether
chang
affect
sc
expans
evalu
procedur
prepar
platelet
concentr
may
includ
leucoreduct
step
use
differ
type
leucoreduct
filter
leucocyt
present
platelet
concentr
lysat
contain
higher
amount
cytokin
influenc
msc
growth
addit
recent
platelet
concentr
suspend
plasma
howev
residu
plasma
may
mitig
transfusionrel
advers
reaction
recipi
use
intraven
therefor
platelet
storag
addit
solut
contain
sodiumpotassium
chlorid
citrat
phosphat
mannitol
may
use
substitut
part
usual
plasma
volum
affect
protein
content
reduc
presenc
plasma
nutrient
pl
howev
gammairradi
bc
pool
tsol
addit
solut
subject
freezethaw
cycl
centrifug
filter
could
use
expand
bmmsc
furthermor
plasmapoor
platelet
concentr
addit
solut
subject
pathogen
reduct
found
suitabl
stimul
bmmsc
growth
mainten
properti
studi
deem
necessari
confirm
absenc
impact
complet
plasma
remov
ex
vivo
expans
msc
bone
marrow
sourc
note
research
institut
util
platelet
concentr
blood
group
donor
possibl
dilut
blood
group
ab
plasma
tabl
summar
signific
characterist
allogen
platelet
concentr
avail
blood
establish
use
current
product
procedur
therapeut
platelet
unit
platelet
count
exceed
limit
accept
residu
leucocyt
content
depend
upon
whether
platelet
concentr
store
plasma
combin
plasma
addit
solut
whether
leucoreduct
step
use
platelet
concentr
store
ae
continu
gentl
agit
bag
made
cellcompat
plastic
enhanc
oxygen
permeabl
diffus
carbon
dioxid
ph
remain
ph
temperatur
may
induc
platelet
activ
releas
platelet
storag
compon
plasma
proper
storag
condit
limit
risk
activ
maintain
unalt
hemostat
state
intraven
infus
agit
enabl
good
mix
ga
exchang
fold
bag
foam
avoid
platelet
compon
transport
hospit
agit
insul
contain
ensur
mainten
optim
storag
temperatur
platelet
use
transfus
store
day
time
longer
use
transfus
discard
expir
platelet
concentr
use
sourc
materi
prepar
growth
factor
prepar
sc
expans
product
may
frozen
colder
process
pl
facilit
logist
prepar
recent
studi
confirm
human
pl
produc
expir
platelet
concentr
suitabl
aspect
evalu
growth
supplement
ex
vivo
expans
bmmsc
differ
pl
fresh
expir
platelet
concentr
observ
blood
donat
subject
aborhd
group
ensur
compat
recipi
blood
compon
serum
abbloodgrouptyp
donor
ab
serum
platelet
groupo
donor
reportedli
use
research
group
sc
expans
also
lysat
platelet
concentr
prepar
bc
collect
bloodgroupotyp
donor
pool
ab
plasma
use
msc
growth
cultur
supplement
countri
matur
regulatori
system
blood
establish
respons
produc
blood
compon
includ
platelet
fraction
strict
qualiti
system
place
base
principl
gmp
compli
local
regul
ensur
qualiti
consist
meet
specif
anticoagul
addit
solut
collect
storag
bag
licens
prepar
equip
valid
premis
maintain
clean
hygien
condit
monitor
prepar
platelet
concentr
pool
done
use
asept
procedur
either
multipl
bag
configur
steril
connect
devic
use
follow
valid
procedur
closedsystem
process
although
variabl
link
individu
donor
elimin
requir
ensur
rel
consist
characterist
variou
type
allogen
platelet
concentr
particularli
platelet
leucocyt
count
use
prepar
pl
sc
expans
contribut
higher
reproduc
bloodborn
pathogen
tabl
show
relev
bloodborn
pathogen
indic
rel
risk
transmiss
variou
class
blood
product
inform
found
variou
review
intern
guidelin
risk
transmiss
plasmaborn
virus
repres
principl
seriou
infecti
concern
use
pl
cell
therapi
regen
medicin
among
envelop
virus
hiv
hepat
b
viru
hbv
hcv
pathogen
although
increas
concern
risk
pose
emerg
agent
like
wnv
dengu
denv
chikungunya
chikv
virus
well
nonenvelop
hav
parvoviru
hev
microbi
filtrat
pl
mm
prior
addit
cultur
medium
ensur
remov
bacteria
parasit
addit
freezethaw
step
use
produc
pl
destroy
parasit
far
four
record
case
transmiss
new
vcjd
diseas
agent
cellular
blood
compon
collect
uk
yet
evid
transmiss
vcjd
blood
product
includ
pool
plasma
product
point
current
vcjd
safeti
human
blood
compon
includ
pl
reli
epidemiolog
popul
control
leucoreduct
blood
compon
prionremov
filtrat
least
blood
compon
blood
donor
test
vcjdposit
donat
develop
allogen
platelet
concentr
use
ex
vivo
expans
clinicalgrad
msc
compli
qualiti
safeti
regulatori
requir
establish
nation
regulatori
author
product
blood
compon
transfus
countri
advanc
bloodcollect
servic
matur
regulatori
system
wellestablish
safeti
net
place
prepar
blood
compon
safeti
measur
includ
epidemiolog
control
popul
blood
collect
b
screen
donor
c
test
blood
donat
known
viral
marker
addit
strict
traceabl
system
place
potenti
perform
backtrac
donor
retrospect
found
risk
factor
blood
donat
individu
control
use
approv
test
least
antibodi
hepat
b
surfac
antigen
hbsag
hcv
antibodi
nonreact
donat
use
therapeut
applic
specif
epidemiolog
situat
may
requir
test
agent
marker
antihuman
tcell
leukemia
viru
htlv
iii
wnv
nucleic
acid
test
nat
individu
donat
minipool
hcv
hbv
hiv
hav
wnv
appropri
andor
perform
new
biotechnolog
volum
number
januari
research
paper
approxim
per
donat
hbv
constant
exposur
blood
suppli
emerg
virus
wnv
denv
chikv
might
test
yet
could
regard
justifi
implement
viralinactiv
treatment
blood
compon
includ
platelet
concentr
sc
expans
limit
number
countri
mostli
europ
two
technolog
viral
inactiv
platelet
concentr
transfus
licens
target
bind
alter
nucleic
acid
photoactiv
process
one
procedur
use
mm
synthet
psoralen
amotosalen
hydrochlorid
small
solubl
planar
molecul
pass
cell
membran
capsid
virus
revers
intercal
helic
region
nucleic
acid
upon
illumin
ultraviolet
uva
nm
coval
cross
link
pyrimidin
rna
dna
gener
block
replic
transcript
viral
nucleic
acid
randomdonor
apheresi
platelet
suspend
plasma
without
addit
solut
process
system
residu
amotosalen
free
photoproduct
gener
illumin
reduc
exposur
compoundadsorpt
devic
treatment
platelet
concentr
transfer
storag
contain
second
procedur
combin
riboflavin
vitamin
photosensit
natur
occur
compound
uv
nm
illumin
riboflavin
planar
molecul
intercal
base
dna
rna
upon
uv
illumin
riboflavin
gener
reactiv
oxygen
speci
oxid
guanin
nucleic
acid
caus
strand
breakag
genom
materi
virus
preclud
prolifer
riboflavin
photobyproduct
form
lumichrom
gener
regard
nontox
therefor
elimin
studi
perform
platelet
concentr
store
plasma
recent
treatment
appli
bc
platelet
concentr
bcpc
apheresi
platelet
concentr
illumin
without
addit
photosensit
vitro
data
indic
viral
inactiv
platelet
concentr
photoactiv
method
lead
degre
platelet
activ
whether
alter
significantli
influenc
use
viral
inactiv
platelet
concentr
sc
expans
known
psoralenuvtr
human
serum
found
appropri
vitro
product
clinicalgrad
islet
langerhan
treat
type
diabet
msc
treat
graft
versu
host
diseas
gvhd
grade
iii
iv
cell
immun
therapi
malign
melanoma
recent
plasmapoor
platelet
addit
solut
subject
pathogen
reduct
psoralenuv
treatment
follow
cycl
freezingthaw
centrifug
remov
membran
found
stimul
msc
growth
clinicalscal
cultur
absenc
viral
inactiv
treatment
quarantin
pl
donor
retest
viral
marker
option
recent
year
prepar
pl
pool
least
donat
trend
increas
product
batchtobatch
consist
howev
pool
increas
need
implement
dedic
viralinactiv
treatment
pl
use
clinicalgrad
sc
expans
solventdeterg
sd
treatment
develop
inactiv
lipidenvelop
virus
eg
hiv
hbv
hcv
plasma
adapt
pool
pl
supplement
ex
vivo
sc
expans
use
regen
medicin
treatment
contribut
extens
releas
platelet
growth
factor
pool
allow
prepar
standard
product
usabl
supplement
growth
medium
ex
vivo
expans
atmsc
prolifer
rate
atmsc
similar
better
achiev
use
fb
supplement
expand
msc
preserv
typic
immunophenotyp
least
seven
passag
exhibit
unalt
differenti
capac
osteogen
chondrogen
adipogen
lineag
sd
treatment
use
year
plasma
product
industri
excel
efficaci
safeti
robust
inactiv
lipidenvelop
virus
howev
sd
treatment
impact
nonenvelop
virus
potenti
requir
combin
anoth
viralreduct
step
due
product
mode
storag
room
temperatur
platelet
concentr
risk
contamin
adventiti
bacteria
mostli
result
improp
donor
arm
clean
time
venipunctur
improv
donor
screen
skin
disinfect
bacteri
screen
reduc
risk
bacteri
screen
implement
part
qualif
platelet
unit
intend
use
prepar
pl
sc
expans
two
pathogen
inactiv
techniqu
singl
platelet
donat
describ
also
inactiv
wide
rang
bacteria
therefor
use
regard
sd
treatment
also
shown
alter
capac
complement
system
plasma
inactiv
gramneg
bacteria
also
gramposit
bacteria
principl
platelet
activ
either
adhes
molecul
expos
injur
endothelium
von
willebrand
factor
vwf
collagen
fibronectin
laminin
physiolog
agonist
thrombin
adp
collagen
thromboxan
epinephrin
plateletactiv
factor
howev
practic
limit
number
method
prepar
pl
allogen
autolog
platelet
concentr
fig
develop
prepar
supplement
sc
expans
procedur
pl
obtain
freezethaw
cycl
thrombin
activ
pl
mostli
produc
autolog
allogen
whole
blood
allogen
apheresi
platelet
concentr
best
knowledg
limit
applic
use
autolog
apheresi
platelet
concentr
due
technic
regulatori
restrict
use
apheresi
system
prepar
method
use
allogen
platelet
concentr
howev
adapt
concentr
autolog
origin
autolog
platelet
materi
use
clinic
applic
small
popul
msc
need
possibl
use
rel
low
pl
concentr
expand
applic
autolog
pl
gener
autolog
pl
prepar
activ
human
thrombin
addit
calcium
salt
counterbal
anticoagul
ad
blood
collect
thrombin
calcium
ion
activ
platelet
convert
fibrinogen
fibrin
result
format
platelet
gel
liquid
pl
batroxobin
venom
toxin
bothrop
atrox
also
use
convert
fibrinogen
fibrin
without
immedi
activ
platelet
featur
believ
delay
releas
growth
factor
autolog
singledonor
pl
also
prepar
freezethaw
process
centrifug
g
min
storag
use
data
show
donor
recipientmatch
autolog
pl
feasibl
therapeut
use
cooper
msc
product
plasma
protein
requir
sc
expans
pl
younger
donor
appear
enhanc
msc
expans
lead
morepronounc
osteogen
differenti
sever
studi
describ
prepar
lysat
allogen
platelet
concentr
prepar
whole
blood
one
procedur
whole
blood
ae
ml
centrifug
g
min
isol
bc
fraction
four
bc
unit
blood
group
unit
plasma
blood
group
ab
pool
blood
group
select
meant
avoid
exposur
msc
abo
blood
group
antigen
isoagglutinin
unit
centrifug
g
min
obtain
prp
transfer
storag
bag
inlin
filtrat
deplet
wbc
prepar
lysat
prp
frozen
thaw
minimum
unit
lyse
human
prp
repres
bc
plasma
unit
pool
reduc
impact
individu
donor
variat
mixtur
store
use
thaw
lysat
centrifug
g
min
reduc
presenc
platelet
membran
fragment
may
repres
risk
alloimmun
mhc
class
human
platelet
antigen
altern
method
prepar
pl
describ
wholeblood
donat
four
abbloodgrouptyp
donor
collect
prepar
bcderiv
platelet
concentr
centrifug
whole
blood
concentr
suspend
ab
plasma
sever
protocol
obtain
pl
compar
one
method
use
shock
freez
twice
liquid
nitrogen
follow
min
centrifug
g
also
done
supernat
sterilefilt
filter
store
aliquot
altern
platelet
activ
use
either
human
thrombin
final
concentr
unit
ml
b
mm
mm
epinephrin
c
mm
thrombin
receptoractiv
peptid
trap
min
room
temperatur
gentl
agit
procedur
calcium
use
platelet
activ
prevent
increas
osteogen
differenti
lysat
centrifug
remov
clot
sterilefilt
frozen
thaw
lysat
centrifug
g
min
new
fibrin
clot
may
form
one
procedur
use
leucoreduc
bcderiv
allogen
platelet
whole
blood
ae
ml
frozen
thaw
lysat
obtain
bc
pool
aliquot
store
immedi
use
aliquot
thaw
centrifug
room
temperatur
min
g
remov
cell
debri
reduc
format
aggreg
cell
cultur
lysat
use
medium
supplement
expand
support
immunomodulatori
capac
bmmsc
recent
platelet
concentr
prepar
whole
blood
plateletsml
within
h
blood
collect
wash
subject
three
cycl
freezingthaw
centrifug
g
min
store
lysat
stimul
dentalpulp
sc
use
pl
pl
lysat
whole
bloodderiv
plt
concentr
approxim
ml
subject
four
cycl
freezingthaw
centrifug
g
min
effect
atmsc
expans
mainten
immunophenotyp
prolif
differenti
capac
passag
product
pl
gamma
irradi
bcderiv
platelet
also
report
pl
frozen
store
month
stabl
day
base
capac
expand
bmmsc
one
procedur
platelet
collect
apheresi
healthi
volunt
plt
frozen
soon
collect
subsequ
thaw
heparin
ad
avoid
gel
format
lysat
centrifug
three
time
g
min
elimin
platelet
bodi
lysat
pool
use
gener
expand
msc
bone
marrow
morpholog
phenotyp
differenti
capac
msc
similar
whether
expand
pl
fb
howev
clonogen
effici
prolif
capac
msc
expand
pl
appear
superior
expand
fb
suitabl
preventingtr
alloreactivityrel
immun
complic
procedur
obtain
lysat
freez
follow
thaw
centrifug
g
lysat
found
acceler
bmmsc
prolifer
enhanc
msc
osteogen
differenti
apheresi
platelet
unit
frozenthaw
centrifug
g
min
filter
mm
store
found
use
growth
medium
similar
fb
expand
msc
morpholog
phenotyp
procedur
prepar
pl
use
sonic
recent
describ
apheresi
platelet
concentr
sampl
five
six
donor
pool
ethylen
vinyl
acet
eva
ratio
bag
surfac
platelet
concentr
volum
ultrasound
appli
min
frequenc
khz
condit
found
releas
pdgfab
centrifug
g
min
room
temperatur
supernat
filter
store
pl
enhanc
prolifer
rate
bmmsc
differenti
adipogen
osteogen
chondrogen
lineag
bmmsc
maintain
immunosuppress
activ
cell
karyotyp
show
genet
alter
sever
advantag
use
human
blood
product
sc
expans
first
due
human
origin
product
devoid
immunolog
risk
specif
associ
use
xenoproteinbas
product
second
infrastructur
blood
collect
qualitysafeti
test
well
establish
least
industri
countri
advanc
bloodcollect
system
good
nation
regulatori
supervis
countri
like
us
germani
switzerland
franc
other
blood
product
regul
pharmaceuticalmedicin
product
produc
follow
principl
gmp
contribut
optim
product
consist
viral
safeti
traceabl
recent
guidelin
encourag
concept
gmp
implement
blood
establish
global
level
increas
avail
qualiti
sourc
materi
pl
pl
use
tissu
stemprogenitor
cell
expans
differenti
variou
lineag
vitro
clinic
applic
favor
expans
msc
fb
substitut
regen
medicin
bench
bed
site
sever
studi
determin
protein
composit
pl
particular
growth
factor
content
total
plasma
protein
content
close
gl
composit
differ
depend
upon
use
plateletstabil
solut
least
partial
replac
plasma
addit
content
fibrinogen
coagul
factor
fibronectin
higher
pl
obtain
freezethaw
procedur
compar
produc
activ
thrombin
calcium
chlorid
high
fibrinogen
level
like
requir
addit
anticoagul
heparin
iuml
final
concentr
cultur
medium
cell
cultur
avoid
clot
due
convers
fibrinogen
fibrin
higher
heparin
concentr
may
impair
cellular
prolifer
altern
serumconvert
pl
prepar
calcium
activ
convert
fibrinogen
insolubl
fibrin
ad
medium
mention
platelet
activ
freezethaw
induc
releas
complex
blend
growth
factor
includ
pdgfaa
ab
bb
egf
vegf
bfgf
bdnf
hgf
varieti
cytokin
includ
gcsf
gmcsf
interleukin
il
interferon
ifn
g
present
pgml
level
pl
also
contain
high
concentr
chemokin
particular
attach
factor
fibronectin
vitronectin
cell
adhes
molecul
coagul
factor
mitogen
proteas
inhibitor
proteoglycan
serotonin
potent
biomolecul
rich
content
growth
factor
use
produc
pl
substitut
fb
cultur
expans
msc
deriv
variou
human
tissu
condit
cell
maintain
abil
differenti
enhanc
consist
pool
platelet
concentr
prp
develop
viral
inactiv
treatment
use
sd
treatment
improv
viral
safeti
result
growth
factorrich
pl
demonstr
allow
ex
vivo
expans
atmsc
tabl
provid
indic
rang
growth
factor
content
pl
prp
cytokin
identifi
platelet
play
import
role
cell
prolifer
chemotaxi
cell
differenti
regener
angiogenesi
particular
advantag
prp
nativ
cytokin
present
normal
physiolog
ratio
wide
array
bioactiv
growth
factor
found
lysat
platelet
cell
platelet
alpha
granul
posit
doserespons
relationship
found
platelet
concentr
prolifer
human
msc
prolifer
fibroblast
product
type
collagen
sanchezgonzalez
et
al
review
extens
studi
platelet
growth
factor
peptid
growth
factor
platelet
alpha
granul
prp
mani
discov
undiscov
pl
contain
potent
factor
involv
recruit
tissu
stemprogenitor
cell
site
injuri
interact
thu
stimul
differenti
angiogenesi
critic
msc
cultur
tissu
therapeut
heal
twodimension
differ
gel
electrophoresi
malditof
analys
complementari
western
blot
protein
qualit
quantit
differ
could
observ
variou
type
platelet
materi
also
reveal
fibrinogen
apolipoprotein
differenti
affect
atand
bmmsc
prolifer
show
role
ex
vivo
expans
msc
studi
also
illustr
role
proteom
studi
identifi
impact
known
composit
growth
factor
msc
expans
success
use
msc
regen
repair
requir
surviv
transplant
cell
abil
variou
growth
factor
like
fgf
efg
particular
vegf
promot
surviv
studi
msc
treat
vegf
vitro
msc
carri
vegf
gene
vivo
increas
surviv
stromal
cell
rodent
heart
undergon
myocardi
infarct
inject
msc
along
vegf
show
higher
number
msc
inject
site
surg
msc
surviv
attribut
increas
akt
signal
caus
reduct
infarct
size
less
fibrosi
increas
vascular
thicker
ventricular
wall
pdgf
potent
mitogen
connect
tissu
cell
exert
function
interact
relat
receptor
tyrosin
kinas
promot
cellular
prolifer
inhibit
apoptosi
igf
mediat
mani
growthpromot
effect
growth
hormon
tgfb
known
influenc
cell
chondrogen
lineag
vivo
promot
initi
stage
mesenchym
condens
prechondrocyt
prolifer
product
extracellular
matrix
ecm
deposit
cartilagespecif
molecul
inhibit
termin
differenti
appli
msc
vitro
studi
chondrocyt
regener
cell
show
increas
prolifer
bia
toward
chondrogen
lineag
three
isoform
type
induc
prolifer
msc
chondrocyt
format
exhibit
pronounc
effect
chondrogenesi
consist
increas
prolifer
msc
make
prime
factor
induc
chondrogenesi
implant
msc
similarli
bone
morphogen
protein
bmp
growth
factor
belong
tgfb
superfamili
known
affect
bone
format
induc
msc
form
osteoblast
greatest
impact
differenti
msc
overexpress
implant
ecm
protein
collagen
hydrogel
system
increas
prolifer
msc
differenti
bone
model
use
studi
cranial
closur
swine
anoth
member
famili
increas
msc
prolifer
sinc
factor
affect
bone
format
differ
rate
greater
effect
prolifer
synergist
pair
growth
factor
use
optim
dose
specif
point
boneregener
process
one
search
synergist
pair
led
combin
treatment
msc
chondrogen
differenti
found
enhanc
msc
selfrenew
cell
capac
differenti
adipocyt
chondrocyt
myocyt
osteocyt
msc
expans
andor
differenti
toward
specif
cell
lineag
stimul
number
growthdifferenti
factor
like
fgf
egf
igf
pdgf
vegf
wnt
tgfb
certain
basic
growth
factor
like
fgf
egf
promot
msc
expans
without
induc
differenti
other
addit
prolif
prosurviv
effect
also
induc
differenti
msc
toward
specif
lineag
exampl
tgfb
increas
prolifer
msc
induc
chondrogenesi
similarli
increas
msc
prolifer
induc
osteogenesi
tgfb
signal
occur
tgfb
factor
famili
bind
type
ii
serinethreonin
kinas
receptor
recruit
anoth
transmembran
protein
receptor
receptor
phosphoryl
new
biotechnolog
volum
number
januari
research
paper
approxim
content
growth
factor
human
platelet
lysat
growth
factor
content
ngml
plateletderiv
growth
factor
pdgf
ab
pdgfbb
tumor
growth
factor
tgf
brainderiv
neurotroph
factor
bdnf
vascular
endotheli
growth
factor
vegf
endotheli
growth
factor
egf
insulinlik
growth
factor
igf
wwwelseviercomlocatenbt
primari
intracellular
downstream
molecul
eg
sma
mad
relat
protein
smad
caus
transloc
nuclei
specif
gene
transcript
receptor
signal
smad
smad
signal
smad
smad
signal
via
smad
smad
smad
requir
msc
chondrocyt
differenti
signal
smad
smad
block
chondrocyt
differenti
tgfb
member
growth
factor
famili
also
signal
via
mitogenactiv
protein
kinas
mapk
rho
gtpase
kinas
pathway
msc
effect
prolifer
osteogen
differenti
msc
shown
occur
via
sustain
signal
mapk
extracellular
signalregul
kinas
erk
mitogen
effect
hand
found
mediat
tgfbactivin
signal
mapk
signal
pathway
smad
smad
key
player
involv
msc
prolifer
differenti
msc
pretreat
tgfa
exhibit
increas
surviv
improv
also
attribut
vegf
signal
although
direct
signal
egf
receptor
egfr
discount
tgfa
increas
vegf
product
via
mapk
pathway
enhanc
recoveri
therefor
ischem
cardiac
tissu
msc
supplant
vegf
far
best
choic
increas
surviv
lead
improv
vascular
ischem
cardiac
tissu
isol
islet
sever
platelet
growth
factor
proven
increas
msc
surviv
msc
transplant
bdnf
nerv
growth
factor
ngf
rodent
traumat
brain
injuri
produc
significantli
higher
number
engraft
cell
compar
msc
transplant
growth
factor
pdgfbb
found
reduc
loss
cell
apoptosi
seen
day
week
rat
follow
acut
myocardi
infarct
contrari
limit
effect
msc
expans
hgf
caus
slight
increas
msc
surviv
signal
implic
increas
anoth
major
growth
factor
studi
effect
msc
surviv
egf
sinc
initi
studi
show
egf
solubl
state
caus
differenti
msc
enhanc
expans
hypothes
solubl
egf
would
similarli
enhanc
surviv
msc
subject
prodeath
cytokin
fasl
trail
vitro
contrari
expect
solubl
egf
protect
msc
increas
cell
death
presenc
fasl
human
pl
present
pool
bioactiv
molecul
cell
growth
cultur
pdgf
tgfb
famili
cytokin
affect
cell
morphogenesi
prolifer
differenti
found
abund
pl
potenti
influenc
msc
cultur
select
specif
growth
factor
deriv
pl
use
expand
msc
differenti
msc
toward
specif
lineag
pdgfabbb
bfgf
essenti
stimuli
prolifer
msc
three
factor
bfgf
pdgfbb
seem
necessari
optim
prolifer
msc
howev
three
factor
insuffici
even
use
cell
cultur
multiwel
plate
coat
human
fibronectin
human
placent
collagen
iiii
therefor
addit
essenti
compon
pdgfbb
bfgf
constitu
pl
import
full
biolog
activ
platelet
concentr
obtain
byproduct
rbc
concentr
made
whole
blood
prepar
apheresi
recent
survey
indic
approxim
million
wholeblood
donat
global
major
collect
countri
high
medium
develop
index
although
blood
donat
current
use
prepar
platelet
concentr
figur
provid
idea
volum
platelet
concentr
potenti
avail
use
sc
expans
base
mean
volum
ml
platelet
concentr
per
donat
also
establish
pl
produc
expir
platelet
concentr
suitabl
supplement
sc
expans
substanti
wellestablish
scientif
evid
pl
releas
use
replac
fb
ex
vivo
expans
sc
allogen
materi
present
advantag
avail
worldwid
sideproduct
prepar
rbc
concentr
far
major
driver
wholeblood
collect
world
addit
apheresi
procedur
implement
dedic
collect
platelet
concentr
need
principl
gmp
donor
screen
viral
test
traceabl
product
monitor
etc
place
collect
blood
compon
use
tradit
transfus
manufactur
need
constitut
profession
framework
definit
support
qualiti
safeti
requir
allogen
platelet
concentr
sourc
materi
prepar
growth
factorrich
pl
therapeuticscal
sc
expans
regen
medicin
addit
possibl
perform
autolog
platelet
collect
repres
altern
sourc
pl
small
expans
cultur
volum
accept
reach
clinic
meaning
msc
number
one
expect
improv
ex
vivo
expans
msc
clinic
applic
allow
develop
fulli
autolog
treatment
procedur
believ
human
pl
made
wellcontrol
platelet
concentr
sourc
product
procedur
potenti
becom
next
clinicalgrad
gold
standard
supplement
isol
ex
vivo
expans
sc
